RapidAI wins FDA clearance for LVO identification

2020 08 11 23 26 7074 Computer Heart2 400

Artificial intelligence (AI) software developer RapidAI has received clearance from the U.S. Food and Drug Administration (FDA) for its software that detects suspected large-vessel occlusions (LVO).

Rapid LVO identifies suspected LVOs using vessel tracking and assessment of brain regions with reduced blood vessel density. It analyzes images in as few as three minutes and has a sensitivity of 97% and specificity of 96%, according to the company.

Page 1 of 366
Next Page